Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis
Authors
Mark T. Osterman (ORCID: https://orcid.org/0000-0002-9962-1143)
Erik DeBoer
Anthony Krakovich
O. P. Alexeeva (ORCID: https://orcid.org/0000-0002-1475-6584)
P. Sinh
A Jain
Jon Riolo
Dimpy Mehra
JA Cohen
James Appio
Silvio Danese
Douglas C Wolf
AnnKatrin Petersen
Peter Irving
Zhaohui Liu
Hiroshi Nakase
David T Rubin
Bruce A. C. Cree
Institutions
Cleveland Clinic (US)
Sapporo Medical University (JP)
University of California, San Francisco (US)
Guy's and St Thomas' NHS Foundation Trust (GB)
Medical College of Wisconsin (US)
University of Chicago (US)
Nizhny Novgorod Regional Clinical Hospital named after Semashko (RU)
Bristol-Myers Squibb (United States) (US)
Nizhny Novgorod Regional Clinical Oncology Center (RU)
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis
Mark T. Osterman, Erik DeBoer, Anthony Krakovich, O. P. Alexeeva et al.
Journal
Inflammatory Bowel Diseases
Topics
Multiple Sclerosis Research Studies
article
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis
Mark T. Osterman, Erik DeBoer, Anthony Krakovich, O. P. Alexeeva, P. Sinh, A Jain, Jon Riolo, Dimpy Mehra, JA Cohen, James Appio, Silvio Danese, Douglas C Wolf, AnnKatrin Petersen, Peter Irving, Zhaohui Liu, Hiroshi Nakase, David T Rubin, Bruce A. C. Cree
article en
Abstract
No abstract available for this paper.
Publication Tag
Inflammatory Bowel Diseases
Institutions
Cleveland Clinic (US), Sapporo Medical University (JP), University of California, San Francisco (US), Guy's and St Thomas' NHS Foundation Trust (GB), Medical College of Wisconsin (US), University of Chicago (US), Nizhny Novgorod Regional Clinical Hospital named after Semashko (RU), Bristol-Myers Squibb (United States) (US), Nizhny Novgorod Regional Clinical Oncology Center (RU), IRCCS Ospedale San Raffaele (IT), Atlanta Gastroenterology Associates (US), Icahn School of Medicine at Mount Sinai (US)